This review is focused on recent investigations demonstrating a pharmacolog
ical and pathophysiologic role in gastroduodenal ulceration for growth fact
ors such as basic fibroblast growth factor (bFGF), platelet-derived growth
factor (PDGF) and vascular endothelial growth factor (VEGF), as well as for
transcription factors. Our experiments revealed accelerated healing, witho
ut decreased gastric acid secretion, of chronic cysteamine-induced duodenal
ulcers in rats treated daily for 3 weeks with intragastric administration
of bFGF, PDGF or VEGF. Our recent studies also indicate a pathophysiologica
l role of endogenous growth factors in the natural history of experimental
duodenal ulcer development and healing.
More recently, we investigated the genetic regulation of these growth facto
rs in experimental duodenal ulceration. Since gene expression is most effec
tively controlled by transcription factors, proteins that bind to cis-actin
g elements of DNA and guide the binding of polymerase II to start the trans
cription of specific mRNA, we tested the hypothesis that the expression of
IEGs and their transcription factor products, such as Egr-1 and Sp1, might
precede the increased synthesis of bFGF, PDGF and VEGF in duodenal ulcer he
aling. Indeed, the duodenal ulcerogen cysteamine, but not its nonulcerogen
and toxic analogue ethanolamine, rapidly increased duodenal (but not gastri
c) mucosal levels of ET-1, which was followed by enhanced expression of Egr
-1 and a decrease in Sp1 in the preulcerogenic stage of duodenal ulceration
. These changes in levels of ET-1 and expression of transcription factors w
ere also accompanied by increased expression of the CDK inhibitor p21. Thus
, not only growth factors such as bFGF, PDGF and VEGF, but also transcripti
on factors such as Egr-1 and Sp1 and the cell cycle regulator p21, may play
a role in the natural history of experimental duodenal ulceration.